Biomarkers for type 2 diabetes and complications
Investigation of biological markers to describe and predict the progression of prediabetes to type 2 diabetes and associated complications
1. RHAPSODY – ”Risk Assessment and ProgreSsiOn of Diabetes”
The RHAPSODY consortium aims to identifying, characterizing and validating biomarkers for onset of diabetes / diabetes progression in order to enable disease modification. By combining clinical and genetic data from several European cohorts, changes in glucose metabolism before and after diabetes onset will be assessed in order to establish biomarkers of glucose dysregulation potential involvement of genetic factors.
RHAPSODY involves several academic and industrial partners, where SDCC works particularly with the Lund University Diabetes Centre, (Malmö, Sweden), the Swiss Institute of Bioinformatics (Lausanne, Switzerland) and Novo Nordisk (Måløv, Denmark).
2. Methylglyoxal – a potential marker of diabetic complications
Although diabetes is primarily characterized by disturbances in the regulation of glucose, other factors may be involved: Methylglyoxal, a by-product of glucose metabolism, may play a role in the progression toward diabetes and associated complications. The potential involvement of methylglyoxal may help explain why some diabetic patients, despite having good glucose control, go on to develop complications. Further insight into these mechanisms may help determine which patients are at high risk of developing complications and at the same time provide a basis for new therapeutic approaches. The project therefor aims to assess the role of methylglyoxal (and molecules derived from methylglyoxal, the ‘advanced glycation end-products’) in kidney disease, neuropathy as well as cardiovascular disease.
The project is based on a collaboration with the University of Heidelberg (Heidelberg, Germany).